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ABSTRACT
DAX-1 is an orphan nuclear receptor that plays a key role in the
development and function of the adrenal gland and hypothalamic-
pituitary gonadal axis. Mutations in the gene encoding DAX-1 result
in X-linked adrenal hypoplasia congenita (AHC). Affected boys typ-
ically present with primary adrenal failure in infancy or childhood
and hypogonadotropic hypogonadism at the time of puberty. The
majority of DAX1 mutations described to date are nonsense or frame-
shift mutations that result in premature truncation of the DAX-1
protein and loss of DAX-1 repressor function. Relatively few missense
mutations in DAX1 have been reported. Here, we describe missense
mutations in three additional families with X-linked AHC. When
combined with previous reports, the DAX1 missense mutations ap-
pear to cluster within restricted regions of the putative ligand-binding
domain of DAX-1 and affect amino acids that are evolutionarily con-
served, suggesting that these regions correspond to critical functional
domains. Transcription assays, using a variety of artificial and native
target genes, were performed to assess the effects of these mutations
on the function of DAX-1. All DAX-1 missense mutant constructs
showed marked loss of repressor function, with the exception of I439S,
a mutation previously shown to be associated with delayed-onset
adrenal failure and incomplete hypogonadotropic hypogonadism.
These data indicate that most DAX1 missense mutations associated
with classic AHC exhibit marked loss of function. The locations of
these mutations thereby identify important functional domains in the
carboxyl-terminus of the protein. (J Clin Endocrinol Metab 86: 3171–
3175, 2001)
DAX-1 IS A transcription factor that plays a key role inthe development and function of the adrenal gland
and hypothalamic-pituitary-gonadal axis (1–4). Mutations in
the gene encoding DAX-1 (AHC) cause X-linked adrenal
hypoplasia congenita (AHC; OMIM: 300200) (1, 2). Boys with
this condition usually present with primary adrenal failure
in early infancy or throughout childhood (5). The associated
feature of hypogonadotropic hypogonadism (HHG) be-
comes apparent at the expected time of puberty, and there is
increasing evidence from Ahch (Dax1) knockout mice (6) and
a limited number of patients with AHC (7, 8) that DAX-1 may
also influence spermatogenesis directly.
DAX1 encodes a 470-amino acid protein that belongs to the
orphan nuclear receptor superfamily (NR0B1). This protein
has a carboxyl-terminal region that shares sequence homol-
ogy with the ligand-binding domain (LBD) of other nuclear
receptors (1). However, the amino-terminus of DAX-1 con-
sists of a novel 66- to 67-amino acid repeat motif structure not
found in other known transcription factors. No ligand for
DAX-1 has been identified.
The majority of functional data reported suggest that
DAX-1 represses the transcription of several genes expressed
in the adrenal and reproductive axes, either directly or
through an interaction with the related orphan nuclear re-
ceptor steroidogenic factor-1 (SF-1) (9). Some studies have
suggested that this repressor function may involve specific
transcriptional silencing domains within the carboxyl-termi-
nus of DAX-1 (10), whereas others have proposed that DAX-1
can bind directly to hairpin loop structures in the promoters
of certain target genes (11). Further, direct interactions be-
tween DAX-1 and repressors such as nuclear receptor core-
pressor (NCoR) (12) and Alien (13) have been described. The
relative importance of these mechanisms in the regulation of
different target genes remains unclear.
Over 60 different mutations in DAX-1 have now been
reported in patients and families with X-linked AHC [for
review, see Refs. 5 and 14]. The majority of these mutations
are nonsense or frameshift mutations that cause premature
truncation of the carboxyl-terminus of DAX-1. In fact, loss of
as little as 9 amino acids at the carboxyl-terminus of DAX-1
is sufficient to impair DAX-1 function and to produce a
clinically severe phenotype (15). In contrast, missense mu-
tations or single codon deletions in DAX-1 are relatively rare;
only 15 different mutations have been reported to date in
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published reports or abstracts involving 16 individuals or
families with X-linked AHC (2, 8, 16–24). Although the ma-
jority of these children present early in life, an I439S missense
mutation in DAX-1 was reported recently in a patient who
presented first in adulthood with mild adrenal insufficiency
and partial HHG (8).
The identification of additional DAX1 missense mutations
may be useful to define critical structural domains involved
in DAX-1 function. Here we report DAX1 missense muta-
tions in three families with X-linked AHC and show that
these and other mutations cluster within certain regions of
the carboxyl-terminus of DAX-1. The functional effects of all
reported DAX-1 missense mutations were assessed in a panel
of established and novel gene transcription assays in an
attempt to determine whether certain regions of DAX-1 are
critical for the regulation of different target genes.
Materials and Methods
DNA sequence analysis
After obtaining institutional review board approval, DNA was ex-
tracted from patients’ blood leukocytes using standard methods. The
two exons, splice sites, and 59-proximal promoter region of DAX1 (2234
nucleotides) were amplified by PCR using six primer pairs and condi-
tions described previously (25). Sequencing reactions were performed in
forward and reverse directions using the dRhodamine sequencing kit
and an ABI377 automated DNA sequencer (PE Applied Biosystems,
Foster City, CA).
Construction of DAX1 expression vectors
DAX-1 expression vectors representing all reported naturally occur-
ring missense mutants and single codon deletions were created using
standard overlapping PCR strategies and wild-type human DAX1 com-
plementary DNA (cDNA) as a template. In addition, an artificial trans-
activating function-2 (AF2) domain missense mutant (C467S) was cre-
ated that was expected to have wild-type function and served as a
negative control. Further, an AF2 deletion mutant (del448–470) was
created as a positive control for loss of DAX-1 repressor function, as
reported previously (9). Direct sequencing of all plasmids was per-
formed to confirm the presence of the mutations.
Basal transcriptional activity
The effects of DAX-1 and its mutants on basal transcriptional activity
were investigated using a modified mammalian two-hybrid system (8,
9). For these studies, cDNA corresponding to the putative LBD of DAX-1
(codons 207–470) was inserted into a pBIND expression vector (Promega
Corp., Madison, WI) and linked to a GAL4 DNA-binding domain to
allow expression of wild-type and mutant GAL4-DAX-1 fusion proteins.
These expression vectors (50 ng) were cotransfected with a UAS-
TK109luc reporter (500 ng) containing two GAL4-binding sites (9).
SF-1 mediated trans-activation
The effects of DAX-1 and its mutants on SF-1-mediated trans-activa-
tion was studied using full-length wild-type or mutant DAX1 cDNA in
a pCMX expression vector. The LBD of human SF-1 (FTZF1; codons
133–461) was linked to GAL4DBD in pBIND. These expression vectors
(20 ng SF-1, 50 ng DAX-1) were cotransfected with a UAS-TK109luc
reporter (500 ng) (9).
SF-1/Egr-1 synergistic activation of LHb
The effects of DAX-1 and its mutants on SF-1/Egr-1 synergistic ac-
tivation of the LHb promoter were studied by cotransfecting full-length
human wild-type or mutant pCMXDAX-1 (50 ng), full-length human
pCMXSF-1 (20 ng), and full-length rat early growth response-1 (Egr-1;
20 ng) with a pA3 luciferase reporter containing nucleotides 2154 to 15
of the native rat LHb promoter (26).
SF-1/cAMP synergistic activation of inhibin a
The effects of DAX-1 and its mutants on SF-1/cAMP synergistic
activation of the inhibin a promoter were studied by cotransfecting
full-length human wild-type or mutant pCMXDAX-1 (50 ng), full-length
human pCMXSF-1 (20 ng), and a protein kinase A expression vector (20
ng) with a pGL3 basic luciferase reporter containing nucleotides 2146
to 168 of the native rat inhibin a promoter (27).
Transient transfections
Transient gene expression studies were performed using human em-
bryonic kidney tsa210 cells grown in DMEM supplemented with 10%
FBS and 1% streptomycin/penicillin in a 5% CO2 atmosphere at 37 C.
All transfections were performed in triplicate using calcium phosphate
precipitation. Each experiment was repeated on six separate occasions.
Data for each mutant construct are presented as a percentage of the
DAX-1 empty vector control for that study. Results represent the mean 6
sem from the six independent experiments, each consisting of triplicate
transfections.
Results
Case reports
Kindred 1 (A300P). The proband, a boy of Ashkenazi descent,
was hyponatremic and hyperkalemic at 18 days of age. His
serum aldosterone was undetectable, and PRA was mark-
edly elevated. An initial diagnosis of congenital mineralo-
corticoid deficiency was made, and he was treated with
9a-fludrocortisone. However, he became progressively hy-
perpigmented, and reevaluation at 2 yr of age revealed hy-
pocortisolemia (,1 mg/dL; 30 nmol/L) and elevated ACTH
(.2000 pg/mL; .400 pmol/L), consistent with primary ad-
renal failure. DAX1 sequence analysis revealed a hemizy-
gous A300P mutation.
Kindred 2 (A300P). The proband, a male nonidentical twin,
was born at 36 weeks gestation by cesarian section. He de-
veloped progressive hyponatremia and hyperkalemia in the
first 2 weeks of life. Investigations of adrenal function re-
vealed an impaired cortisol response to ACTH stimulation
(16 3 19 mg/dL; 450 3 530 nmol/L), low aldosterone (3.1
ng/dL; 86 pmol/L), and elevated ACTH (348 pg/mL; 76
pmol/L) and 11-deoxycortisol (2372 ng/dL; 68.5 nmol/L).
Gonadotropins were detectable (FSH, 4.2 mIU/mL; LH, 1.8
mIU/mL), and testosterone at 1 month of age was within the
normal range (187 ng/dL; 6.5 nmol/L). A diagnosis of ad-
renal hypoplasia congenita was considered, and a hemizy-
gous A300P mutation was found in DAX1.
Kindred 3 (E377K). The proband presented with a salt-losing
crisis at 1 month of age. A diagnosis of 21-hydroxylase
deficiency was considered, and he was started on glucocor-
ticoid and mineralocorticoid replacement. However, 17-
hydroxyprogesterone remained low despite variable com-
pliance with treatment. Analysis of DAX1 revealed an E377K
mutation.
Clustering of missense mutations in DAX-1
These DAX-1 missense mutations in three kindreds
(A300P, A300P, and E377K) and the two we described re-
cently [L381H (22) and I439S (8)] are all located within the
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carboxyl-terminal region of the DAX-1 protein. When taken
together with other reported DAX-1 mutations, a potential
clustering of affected amino acids within three regions of the
putative LBD is suggested (Fig. 1). These regions may rep-
resent critical domains for DAX-1 function.
Transient gene expression assays
A variety of transient gene expression assays were devel-
oped to assess the effects of DAX-1 missense mutants on the
transcription of potential target genes. As reported previ-
ously, wild-type DAX-1 was a potent repressor of basal tran-
scriptional activity (Fig. 2A) (9) as well as of SF-1-mediated
trans-activation (Fig. 2B) (9) and SF-1/Egr1 synergistic acti-
vation of the native LHb gene promoter (Fig. 3A) (8, 28). In
addition, we show that wild-type DAX-1 represses syner-
gistic activation of the inhibin a gene promoter by SF-1/
cAMP (Fig. 3B).
The library of naturally occurring DAX-1 missense mu-
tants showed a loss of repressor activity in all of these assay
systems (Figs. 2 and 3). In most cases the loss of function was
equivalent to that seen with a mutant construct containing a
deletion of the DAX-1 carboxyl-terminal region (del448–
470). The effects of these missense mutations on DAX-1 func-
tion are consistent with the clinically severe phenotype and
early onset of adrenal failure seen in most of these patients
(Fig. 4). Of note, the I439S missense mutation, found in a
patient who presented first in adulthood, had partial loss of
repressor function (8), which seems unique compared with
the other missense mutations (Fig. 4).
Discussion
The association between DAX-1 and X-linked AHC is well
established, and many frameshift and nonsense mutations in
DAX-1 have been described in patients with this condition.
In contrast, missense mutations in DAX-1 are relatively rare,
but may be important for identifying critical regions or
amino acids necessary for DAX-1 function.
To address this issue, we studied the localization and
functional effects of three newly identified DAX-1 missense
mutations along with 13 others reported in the literature.
These missense mutations are located within certain regions
of the DAX-1 carboxyl-terminus. This clustering of mutations
is most striking between codons 377 and 385, where four
different amino acid mutations have been found, suggesting
that this region represents an important functional domain.
In addition, the description of different mutations within the
same codon (A300V and A300P; R425G and R425T) and the
presence of identical missense mutations in DAX-1 in unre-
lated families with X-linked AHC (del269V; A300P and
E377K), suggests that certain amino acids within these re-
gions have a critical function. Indeed, all DAX-1 missense
mutations reported to date affect amino acids that are con-
served absolutely in all species in which a DAX-1 homologue
has been cloned, including the chicken (29) and alligator (30).
It is particularly striking that no mutations are located within
the amino-terminus of the protein. This finding could be due
to chance. It is also possible that the amino-terminus of
DAX-1 is not important for its function. More likely, the
FIG. 1. Naturally occurring DAX-1 missense mutations cluster
within the carboxyl-terminus of DAX-1 in a region homologous to the
LBD of other nuclear receptors. The repeat motif structure of the
amino-terminus of DAX-1 is shown by arrows. The carboxyl-terminal
putative AF2 domain is shaded. Previously reported potential tran-
scriptional silencing domains are shown by black bars (10).
FIG. 2. Effects of naturally occurring missense mutations in DAX-1
on repressor activity in transient gene expression assays. Upper
panel, The effects of GAL4-DAX-1 and its mutants on basal tran-
scriptional activity. Lower panel, The effects of DAX-1 and its mu-
tants on SF-1-mediated transcriptional activation. Cartoons depict-
ing these gene expression assays are shown to the right of each panel.
Data for each mutant are presented as a percentage (6SEM) of empty
vector activity (100%) for six independent experiments, each per-
formed in triplicate. Dashed lines represent the degree of repression
obtained using wild-type DAX-1.
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repeated nature of the domains within the amino-terminus
may serve redundant functions, such that single amino acid
substitutions are not sufficient to cause complete loss of
function. These findings indicate the value of identifying
naturally occurring DAX-1 missense mutations as a means of
defining important functional domains.
A similar clustering of missense mutations has been re-
ported previously within the LBD of the thyroid receptor
(TRa) in patients with resistance to thyroid hormone (31).
Attempts have been made to map DAX-1 missense muta-
tions to the LBD of the TR, as determined by x-ray crystal-
lography (32). Using this approach, it has been proposed that
DAX-1 missense mutations affect amino acids that form the
hydrophobic core of the DAX-1 LBD (19). These amino acids
may affect subdomain structure rather than ligand binding
and may be involved in ligand-independent interactions
such as dimerization (19). Although our report of additional
missense mutations in these regions adds further evidence to
support clustering in these regions, some caution must be
exercised when comparing DAX-1 to TRa, because their se-
quence homology is limited. Attempts have also been made
to map the sequence of DAX-1 to other nuclear receptors,
such as the retinoic acid receptor, retinoid X receptor, and
peroxisome proliferator-activated receptor ( (10, 19, 20, 33).
Using this approach, the cluster regions I and II seem to map
onto helexes 3, 4, 5 and 8, respectively. Key contact residues
that form between these structures may be disrupted by
missense mutations. However, the validity of this type of
mapping approach will only be known when the crystal
structure of the DAX-1 LBD is determined.
An alternative approach has been to consider which
DAX-1 domains affect its role as transcriptional repressor.
Lalli et al. (10) proposed that there are two transcriptional
silencing domains in DAX-1, shown by the black bars in Fig.
1. Although several of the missense mutants fall within this
region (e.g. R267P, del269,and L466R), many do not. Addi-
tional regions therefore seem to be involved in transcrip-
tional repression. Other studies have proposed that DAX-1
can interact with repressors such as NCoR (12) or Alien (13).
Crawford et al. (12) showed a weak direct interaction be-
tween DAX-1 and NCoR and provided data that DAX-1
repression of SF-1 activation involved NCoR recruitment.
This interaction was impaired by introducing the natural
missense mutant R267P into DAX-1, by deleting the DAX-1
carboxyl-terminus (from codon 369), or by introducing an
artificial point mutation (F449D) into DAX-1 at a position that
is conserved in the potent NCoR-interactive factor, RevErb.
Altincicek et al. (13) showed a direct interaction between
DAX-1 and the novel repressor, Alien. This interaction was
also impaired with a R267P DAX-1 mutant or by deleting the
DAX-1 carboxyl-terminus (del448–470). Finally, some data
suggest that DAX-1 may also function as a ribonucleic acid-
binding protein (34). Detailed investigation of how DAX-1
missense mutations alter its interactions with these repres-
sors remains to be examined.
The different clusters of missense mutants could poten-
tially have varying effects on different target genes. To in-
vestigate this, the library of missense mutants was studied in
a variety of transient gene expression assays. In keeping with
previous findings (8–10, 12, 28), DAX-1 was shown to func-
tion as a repressor of basal transcription, SF-1-mediated
FIG. 4. Functional activity of the DAX-1 missense mutant constructs
compared with age at presentation of affected patients. For each
missense mutant construct, an index of mean repressor function in
relation to wild-type DAX-1 (100%) was calculated using data from all
four gene expression studies.
FIG. 3. Effects of naturally occurring missense mutations in DAX-1
on repressor activity in transient gene expression assays. Upper
panel, The effect of DAX-1 and its mutants on SF-1/Egr-1-mediated
synergistic activation of the native LH b promoter. Lower panel, The
effects of DAX-1 and its mutants on SF-1/cAMP-induced synergistic
activation of the native inhibin a promoter. Results are expressed as
described in Fig. 2.
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trans-activation, and synergistic activation of the native LHb
promoter by SF-1 and Egr-1. In addition, we provide novel
data that DAX-1 represses synergistic activation of the in-
hibin a promoter by SF-1 and cAMP. This effect may be
relevant in the developing adrenal gland and hypothalamic-
pituitary-gonadal axis (27, 35). Introducing point mutations
into DAX-1 impaired repressor activity with each of these
promoters. No difference in loss of repression was found
among the different clusters of mutations in different assays.
This finding suggests that the mechanism of repression by
DAX-1 may be consistent in these different systems.
The only significantly different effect on DAX-1 function
occurred with the I439S mutant. This mutation has partial
function and was discovered in a patient with delayed-onset
adrenal failure and incomplete HHG (8). Further, when re-
pressor activity of these missense mutations was compared
with the age at presentation, the I439S mutation once again
appeared unique. These data provide evidence that other
modifier genes and environmental factors influence the clin-
ical presentation of X-linked AHC significantly, and that a
genotype-phenotype correlation cannot be predicted easily.
In summary, these data show how naturally occurring
missense mutations can be useful in identifying potentially
important domains in DAX-1. Identification of additional
missense mutations will help in this regard. In the future,
crystallographic studies of the DAX-1 LBD will help deter-
mine the structural significance of these regions, and further
studies of the interaction between these domains and puta-
tive corepressors/coactivators will help elucidate their bio-
logical effect in the development and function of the adrenal
gland and hypothalamic-pituitary-gonadal axis.
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